Background. With the emergence of pandemic influenza A ( pH1N1) in 2009, children and youth infected with human immunodeficiency virus (HIV) were vulnerable because of immunologic impairment and the greater virulence of this infection in young persons. Methods. A multicenter study of the immunogenicity of 3 licensed influenza A (H1N1) monovalent vaccines (1 live attenuated and 2 inactivated) was conducted in children and youth with perinatal HIV infection, most of whom were receiving 3 antiretroviral drugs, had CD4% 15, and plasma HIV RNA levels <400 copies/mL. Serum hemagglutinin inhibition assay (HAI) antibody levels were measured and correlated with baseline demographic and clinical variables. Results. One hundred forty-nine subjects were enrolled at 26 sites in the United States and Puerto Rico. Over 40% had baseline HAI titers 40. For subjects aged 6 months to <10 years, 79% and 68%, respectively, achieved a 40-and 4-fold rise in HAI titers after the second dose of vaccine. Three weeks after a single immunization with an inactivated vaccine, similar immunogenicity results were achieved in youth aged 10-24 years. With multivariable analysis, only Hispanic ethnicity and CD4% 15 were associated with achieving both HAI titer 40-and 4-fold rise in titer. Conclusions. Although licensed pH1N1 vaccines produced HAI titers that were considered to be protective in the majority of HIV-infected children and youth, the proportion with titers 40-and 4-fold rise in titer was lower than expected for children without HIV infection. Vaccine immunogenicity was lower in HIV-infected children and youth with evidence of immune suppression.
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The emergence of the influenza A (H1N1) pandemic in the spring of 2009 was of great concern to those who provide medical care to children and youth with human immunodeficiency virus (HIV) infection because of reports of increased risk for hospitalization, severe illness, and mortality among children and youth and rapid spread of the pandemic virus [1] [2] [3] . In addition, there was evidence that infection with or immunization against influenza strains that had circulated in recent years offered little protection against this new strain [4] . Previous studies in children and adults with HIV infection showed that they often have suboptimal immune responses to influenza vaccines and experience greater morbidity with influenza infection, particularly at advanced stages of immunosuppression [5] [6] [7] [8] [9] [10] [11] . Thus, children and youth with HIV infection were vulnerable for multiple reasons: like their age peers, they would be unlikely to have antibodies to the 2009 H1N1 virus; contact with age peers would likely lead to exposure to this novel virus; and HIV infection could impair immune response to the infection or to a vaccine.
Immunization of HIV-infected children and adults with licensed H1N1 2009 monovalent vaccines was recommended as soon as these vaccines became available. To determine whether these new vaccines would induce antibody responses considered to be protective in perinatally HIV-infected children and youth, the International Maternal, Pediatric, Adolescent AIDS Clinical Trials Group (IMPAACT) organized a study (P1089) to measure antibody responses to available, licensed H1N1 2009 monovalent vaccines.
METHODS

Study Design and Vaccines
A multicenter study of the immunogenicity of 3 licensed H1N1 2009 monovalent vaccines was conducted in children and youth with perinatal HIV-1 infection. Vaccine selection was determined by the licensed vaccine in clinical use at the study site. Approximately one half of the study sites administered more than 1 type of the study vaccines. Subjects were grouped based on vaccine received. Group vaccine assignments, description of vaccines, and antigen dose are shown in Table 1 . Two doses of vaccine, 21 days apart, were administered to subjects aged 6 months to <10 years. Subjects aged 10 to <25 years received 1 dose of vaccine.
The primary study objectives were to describe shortterm antibody responses after: (1) a single immunization of children and youth aged 10 to <25 years; and (2) the second immunization in children from 6 months to <10 years of age. Secondary objectives were to assess the antibody response after the first immunization of children aged 6 months to <10 years; to assess persistence of antibody responses 7 months after immunization; and to correlate immune responses with CD4+ cell count, CD4%, antiretroviral use, plasma HIV-1 RNA concentration, and timing of seasonal trivalent influenza vaccine. The specific immunization schedule and laboratory assessments were based on a protocol that was the same at each study site.
Study Population
Subjects were enrolled from 26 IMPAACT clinical sites in the United States and Puerto Rico. Inclusion criteria limited enrollment to perinatally HIV-infected subjects that were aged 6 months to <25 years at the time of entry and received 1 of 3 specific licensed H1N1 2009 monovalent vaccines through local clinical care sources. Informed consent (assent where appropriate) was required, and institutional review boards for human subject research approved the study at each participating site.
Subjects with a history of probable or proven pandemic H1N1 2009 infection, or who had received seasonal live attenuated intranasal influenza vaccine within 2 weeks before scheduled enrollment, or who had received any 2009 H1N1 vaccines before the day of entry were excluded. Additional exclusion criteria were as follows: receipt of immunoglobulin or blood products within 3 months before study entry, use of anticancer chemotherapy or radiation therapy within 36 months preceding study entry, immunosuppression as a result of underlying illness or treatment (other than HIV-1 infection), an active neoplastic disease, long-term use of glucocorticoids equivalent to 2 mg/kg per day of prednisone for more than 2 weeks in the past 6 months, use of high- dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the 6 months preceding enrollment, or the presence of a condition that would place the subject at unacceptable risk of injury or render the subject unable to meet the requirements of the study.
Immunogenicity Assessment
Serum for antibody measurement was collected on the day of study entry and at 3 and 28 weeks after first vaccine on all study participants. An additional serum sample, 2 weeks after the second dose of vaccine, was collected for subjects 6 months to <10 years of age. Sera were shipped to a central laboratory at the University of Colorado for antibody assay. Antibody to H1N1 2009 was measured using a hemagglutinin inhibition assay (HAI) [12] . The antigen for this assay was A/ California/7/2009 virus, supplied by the Centers for Disease Control and Prevention (CDC). For convenience, antibody results were expressed as the reciprocal of the endpoint titer; for example, actual titer of 1/40 was expressed as titer of 40.
Influenza-Like Illness
Information on influenza-like illness (ILI) was solicited at enrollment for the 90-day period before enrollment and at each study visit. Subjects were asked about the presence of specific symptoms, including fever, sore throat, fatigue, cough, coryza, pneumonia, myalgia, headache, nausea or vomiting, and diarrhea. Sites also recorded whether a diagnosis of influenza was made, whether oseltamivir was prescribed, and the results of tests for influenza virus and respiratory pathogens.
Data Management and Analysis
Demographic and clinical data and influenza antibody results were collected on standardized case report forms and submitted to a central data management unit (Frontier Science & Technology Research Foundation, Amherst, NY). The baseline characteristics were summarized by age group, using descriptive measures. The HAI titers were summarized for study participants who were evaluable (eligible for study, received the correct vaccine dose, and had serum tested for antibody). The titers measured were as follows: <10 (considered undetectable and replaced in these analyses by 5), 10, 20, 40, 60, 80, 160, 320, 640, and 1280. Antibody results were described in terms of geometric mean titer (GMT) with 95% confidence interval (CI), fold change from baseline, and proportion with HAI titers 40. For the older study participants, the rates of fold change 4 were compared among the 3 vaccine groups using a Fisher's exact test. Participants who achieved both seroconversion (4-fold rise in titer) and seroprotection (HAI titer 40) were considered complete responders.
Multivariable logistic regression was used to examine covariates in relation to complete responder rate.
RESULTS
Study Population Accrual
From November 5, 2009 to January 7, 2010, 149 subjects were enrolled. The median number of subjects enrolled per site was 4 (range, 2-16). Twenty-five subjects were at least 6 months of age and <10 years of age and 124 subjects were aged 10 years and <25 years. The proportion of subjects <10 years of age is relatively small, 20% of the total, reflective of the aging of the population with perinatal HIV infection in the United States. Figure 1 shows the number of subjects in Groups A, B, and C by age who were immunized and had serum available for antibody testing at protocol-specified times postimmunization.
Demographic and Clinical Characteristics of Study Population
Selected demographic and clinical characteristics of the study population stratified by age group are shown in Table 2 . Mean CD4 counts and median CD4% were within the normal range for both younger and older age groups; only 4% and 15%, respectively, had proportion CD4 cells as <15% of total lymphocytes. The median plasma HIV RNA level was 50 copies/mL for the younger group and 123 copies/mL for the older group, and the majority of subjects in both age groups had HIV RNA levels 400 copies/mL. Data on antiretroviral use at the time of enrollment are shown in Table 2 ; the vast majority of subjects were receiving highly active antiretroviral therapy (HAART).
Influenza-Like Illness and 2009 H1N1 Infection
Information on symptoms of ILI, laboratory or clinical diagnosis of influenza, and use of anti-influenza antiviral drugs was recorded. Decisions regarding diagnosis and treatment were made by site personnel. One younger participant and 1 older participant in Group C were diagnosed with influenza based on clinical symptoms, either immediately before or at the time of study entry; HAI data from these subjects were excluded from analysis. Two additional subjects from the older age stratum were diagnosed with influenza at subsequent visits. One subject from Group B was diagnosed based on symptoms, and 1 subject from Group C had a positive test for 2009 H1N1. Post-baseline data from these 2 subjects were excluded from analysis. Seven subjects received oseltamivir, including the 4 subjects who were diagnosed with influenza. None of the other 3 oseltamivir recipients had laboratory confirmation of the diagnosis, 2 had negative laboratory tests for influenza, and the 3rd had rhinovirus RNA detected by polymerase chain reaction in a nasal wash.
Immunogenicity
Children Aged 6 Months to <10 Years. Antibody results were available for 22 of 25 subjects in the younger age group (6 months to <10 years). The only subject <10 years of age in Group A was excluded because he was not immunized with the standard dose of vaccine. The results from Groups B and C for the <10-year-old subjects were combined (Table 3) , because only 4 of the eligible subjects were in Group B and there were no statistically significant differences between Groups B and C in antibody levels at Figure 1 . Enrollment and follow-up of subjects. Subjects were disqualified and nonevaluable if they failed to meet inclusion criteria or developed an exclusion criterion. A, In Group A, the sole subject aged <10 years and 3 of the 10 year subjects were excluded because of a dosing error. One subject was excluded because of prior receipt of 2009 Influenza A (H1N1) vaccine. B, In Group C, 1 subject aged <10 years was excluded because of flu at study entry. C, In Group C, 1 subject aged 10 years was disqualified because of prednisone treatment and another had flu at study entry. D, In Group B, 1 subject aged 10 years was disqualified because of a flu-like illness. E, In Group C, another subject aged 10 years was disqualified because of a flu-like illness. Abbreviations: DQ, disqualified; ILI, influenza-like illness.
baseline or other time points. Baseline HAI titers were high with 10 of 22 (45%) having titers 40. At the 3-week visit, 15 of 22 (68%) had HAI titers 40 and 13 of 22 (59%) had 4-fold rises in titer. At the 5-week visit, 15 of 19 (79%) had HAI titers 40 and 13 of 19 (68%) had 4-fold rises in titer. Considering only subjects with titers <40 at baseline, 6 of 12 (50%), 7 of 10 (70%), and 5 of 11 (45%) had a 4-fold increase from baseline to weeks 3, 5, and 28, respectively. Hemagglutination inhibition assay titers decreased from week 5 to week 28 in 15 of 18 (83%); 2 of 18 (11%) had no change in titer; and 1 of 18 (6%) had an increase in titer from 10 to 40. Geometric mean titer (95% CI) fell to 52 (30, 91) at week 28 (slightly higher than the baseline value of 32 ), and the proportion of subjects with antibody levels 40 decreased modestly to 67%. Only 38% had antibody levels that were 4-fold higher than preimmunization at week 28.
Subjects Aged 10 to <25 Years. Antibody results for the older age group are summarized in Table 4 . As was seen in the younger subjects, relatively high proportions (41%-57%) of older subjects had HAI antibody titers 40 at enrollment. Among recipients of live-attenuated influenza A 2009 H1N1 monovalent vaccine (Group A), neither the proportion with antibody levels 40 nor the GMT level were significantly different after immunization compared with baseline. Among subjects in Groups B and C (recipients of inactivated monovalent 2009 H1N1 vaccines), GMT levels 3 weeks after immunization were 4.8-fold and 2.9-fold higher, respectively, than baseline levels. Considering only subjects whose baseline titer was <40, the number of subjects who achieved a 4-fold increase in titer at weeks 3 and 28 was 1 of 10 (10%) for Group A (both time points); 16 of 27 (59%) and 16 of 26 (62%), respectively, for Group B; and 8 of 21 (38%) and 2 of 20 (10%), respectively, for Group C. In Groups B and C combined, HAI titers decreased in 85 of 109 (78%) from week 3 to week 28; 13 of 109 (12%) had no change in titer; and 11 of 109 (10%) had an increase in titer. There were no statistically significant differences between Groups B and C in the proportion of older subjects who had titers decrease between week 3 and week 28. Complete Responders. Among subjects in Group A, only 1 was a complete responder. Among subjects less than 10 years of age in Groups B and C, 13 of 21 (62%) were complete responders. Among subjects from 10 to 25 years of age, 53 of 95 (56%) were complete responders. There was not a statistically significant difference in the proportion of subjects who were complete responders between Groups B and C.
Effect of Baseline Characteristics on Complete Antibody Response
Participants of all ages from Groups B and C with HAI data at both baseline and day 21 after first vaccine were included in an analysis of the effect of baseline demographic and clinical variables on the achievement of complete antibody responses (Table 5 ). There was only 1 complete responder in Group A. In univariate analysis, younger age, higher CD4%, Hispanic ethnicity and RNA 400 copies/mL were associated with response to vaccine. There were no statistically significant differences between complete responders and participants who did not achieve both HAI titer 40 and 4-fold rise in titer in the following baseline characteristics: antiretroviral treatment, receipt of seasonal influenza vaccine before H1N1 vaccine, gender, race, or CD8 count. Age, CD4%, baseline HAI titer, ethnicity (Hispanic or not), and baseline HIV-1 RNA (400 or >400 copies/mL) were entered into a multivariable logistic regression model with backwards selection. Only Hispanic ethnicity and baseline CD4% 15 were significant, with P values of .005 and .001, respectively.
DISCUSSION
Although a specific level of antibody to influenza A that is protective against laboratory-confirmed infection has not been defined, HAI titers 40 and/or a 4-fold increase in HAI titer after immunization have been widely accepted as surrogates for protection [13, 14] . It has been noted that the hemagglutinin of the 2009 H1N1 virus seems to be more immunogenic in the monovalent vaccines than expected from studies of previous influenza vaccines [15] [16] [17] . In this study of licensed H1N1 2009 monovalent vaccines, the majority of HIV-infected children and youth who received inactivated vaccines achieved HAI titers of 40 and had a 4-fold rise in titer after a single dose of vaccine. However, the proportion of subjects achieving a HAI titer 40 was not as high as reported in studies of HIV-uninfected children, especially considering the high proportion of children in the current study that had preimmunization titers 40. Among HIV-infected children 6 months to <10 years of age, 68% had an antibody titer 40 3 weeks after their first dose of vaccine. A previous study of 3-to 8-year-old, HIV-uninfected children evaluated a 15-µg dose of the vaccine used in Group B in the current study [18] . After a single dose, 72% of HIV-uninfected children had HAI titers 40; however, only 26% of HIV-uninfected children had baseline HAI titers 40 compared with 45% in HIV-infected children in the current study. In another study of HIV-uninfected children, aged 6 months to 9 years, vaccinated with 15 µg per dose of the same vaccine given to Group C in the current study, 62% had a titer 40 after the first dose [19] . However, only 3%-8% of these HIV-uninfected children had detectable HAI antibody to 2009 H1N1 at baseline. Compared with results of the current study, much better immunogenicity was reported in other studies of HIV-uninfected children from 6 months to 13 years of age [20] and from 6 months to <9 years of age [16] who received 7.5 µg or 15 µg, respectively, of unadjuvanted, split cell H1N1 monovalent vaccines. In the current study, 71% of subjects from 10 to 24 years of age achieved an HAI titer 40 after a single dose of inactivated vaccine; 48% had titers 40 at baseline. In HIV-uninfected subjects 9-17 years of age who were immunized with 15 µg or 30 µg of the same unadjuvanted vaccine given to Group B in the current study, 96% and 100%, respectively, achieved HAI antibody titers 40 [18] . Multiple other studies have reported lower immunogenicity of influenza vaccines and lower proportions of HIV-infected vaccinees achieving protective HAI antibody titers than in persons without HIV infection [5, 8, 11, [21] [22] [23] [24] [25] .
Baseline antibody levels were relatively high in this study; 45% of subjects from 6 months to 9 years of age and 48% of subjects from 10 to 24 years of age had baseline titers 40. It is very likely that this finding is the result of ongoing, unrecognized 2009 H1N1 pandemic influenza activity. The first subject was enrolled on November 5, 2009. Records from the CDC influenza surveillance program show that peaks in laboratory-confirmed cases of 2009 H1N1 infection, pediatric hospitalizations, and deaths occurred before that date [26] . It is not surprising that only 3 subjects were diagnosed with influenza at or before enrollment. Most influenza would have resulted in mild illness for which medical attention was not sought. In addition, the clinical diagnosis of influenza in children, including 2009 H1N1 influenza, is not very accurate [27, 28] . The fact that approximately one-half of the subjects in this study had baseline HAI antibody levels that are considered protective means that the proportion of subjects with postvaccine titers 40 overestimates vaccine immunogenicity in HIV-infected children and youth.
A more stringent definition of response to vaccine for the current study required an HAI antibody titer of 40 and a 4-fold increase in titer over baseline; participants who met both criteria were considered complete responders. With multivariable analysis, only baseline CD4% 15 and Hispanic ethnicity had a statistically significant association with complete response to vaccine. It is not clear why Hispanic ethnicity was associated with better response. However, it is interesting that a study in Costa Rica in which 99% of the study population was Hispanic reported unexpectedly high rates of seroprotection (HAI 40) and seroconversion (4-fold rise in titer) in HIVuninfected children after a single dose of monovalent 2009 H1N1 vaccine [18] .
The current study is limited in its ability to assess clinical and laboratory indicators of control of HIV infection because the study population was relatively homogenous and the sample size was small. The sample size was small because the study was opened as the pandemic progressed and after licensed vaccines were available to the public. Children with HIV infection were listed in the top priority group for immunization when the H1N1 2009 monovalent vaccines were initially available to the public. At some sites, potential study subjects had already received vaccine from their healthcare providers before opening of this study. In addition, potential subjects were excluded because of history of influenza-like illness, further limiting the pool of eligible subjects. The study is also limited in its ability to evaluate antibody responses in subjects with no prior immunity to 2009 H1N1 because of the relatively high proportion of subjects with antibody to the virus at baseline.
Other studies of HIV-infected adults and children have reported poor immunogenicity of influenza A vaccines even in HIV-infected patients on HAART, with low or undetectable viral load and normal CD4 counts [22, 25] . In addition, an association between poor response to influenza vaccines and higher viral load and/or lower current or nadir CD4 counts has been reported [21, [29] [30] [31] . Studies of AS03-and MF59-adjuvanted vaccines in healthy adults and children report higher rates of seroprotection and seroconversion or achievement of comparable immunogenicity with much smaller doses of antigen with adjuvanted vaccine [18, 20, 32, 33] . A study comparing immunogenicity of adjuvanted (MF59) and unadjuvanted seasonal influenza vaccine in HIV-negative and HIV-positive adults demonstrated similar rates of seroprotection with each, but higher GMT to influenza A with the adjuvanted vaccine [34] . A safety and immunogenicity study (IMPAACT protocol 1088) reported better immunogenicity in 10-to 24-year-old HIV-infected subjects after two 30-µg injections than was observed in the current study with the manufacturer's recommended single 15-µg injection [35] . In both 1088 and 1089 studies, antibody to monovalent H1N1 2009 vaccine in HIV-infected subjects did not reach levels associated with protection as consistently as reported in uninfected children and youth. Strategies to optimize vaccine protection of HIV-infected children and youth from influenza are needed.
